Harr Steve 4

What Happened
Steve Harr, President & CEO and a director of Sana Biotechnology (SANA), was granted a total of 1,100,000 restricted stock units (RSUs) on 2026-03-05. The grants reported are: 200,000 RSUs and 900,000 RSUs, each recorded at $0.00 (these are derivative awards, not open-market purchases, so no cash was exchanged at grant).

Key Details

• Transaction date: 2026-03-05; Form 4 filed 2026-03-06 (timely).
• Grants: 200,000 RSUs and 900,000 RSUs; grant price reported as $0.00; total awarded = 1,100,000 RSUs.
• Footnote F1: Each RSU represents a contingent right to one share of Sana common stock.
• Footnote F2: These RSUs vest in four equal annual installments on March 5 of 2027, 2028, 2029 and 2030, subject to continued service.
• Footnote F3: The filing also references an option vesting schedule (25% on March 5, 2027 then monthly over 36 months), but the reported 1.1M units here are RSUs per F1–F2.
• Shares owned after the transaction: not specified in the information provided.

Context

• RSU grants are compensation awards that convert to shares only as they vest; they do not represent immediate cash proceeds or open-market buying/selling.
• Such grants are common for executives and reflect compensation structure rather than a direct market sentiment signal.
• This Form 4 filing appears timely (filed the day after the grant date).